Comparing low-dose anticoagulation to standard therapy after left atrial appendage closure
Official title: Low-dose Rivaroxaban Monotherapy Versus Guideline Determined Medication Therapy After Left Atrial Appendage Occlusion: a Randomized, Open-label, Multicentre, Superiority Trial
Run by Xijing Hospital · NCT05960721 · Data updated 2026-11-12
This study is testing if low-dose blood thinners are just as good or better than standard treatment for people with atrial fibrillation after they have had a procedure to close off a part of their heart.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 4220 (estimated) |
| Sponsor | Xijing Hospital Academic / other |
| Locations | 1 site (Xi'an, Shannxi) |
| Status | Recruiting |
| Started | July 6, 2023 |
| Main results expected | July 30, 2025 |
| Study ends | July 30, 2028 |
| Registry record updated | July 27, 2023 |
| Trial ID | NCT05960721 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with non-valvular atrial fibrillation who have successfully undergone left atrial appendage occlusion.
✕Probably not a fit
Patients under 18, those unable to provide informed consent, or with life-threatening comorbidities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of low-dose novel oral anticoagulants (NOACs) compared to guideline-directed medical therapy (GDMT) in patients with non-valvular atrial fibrillation who have undergone successful left atrial appendage occlusion (LAAO). The trial aims to determine if low-dose anticoagulation can provide similar or improved outcomes in preventing thromboembolic events. Participants will be monitored for stroke, systemic embolism, and device-related complications while receiving either low-dose NOACs or standard therapy. The findings could help refine post-LAAO management strategies for patients with atrial fibrillation.
Why it matters
Potential benefit: If successful, this study could lead to more effective and safer anticoagulation strategies for patients with atrial fibrillation after LAAO.
How similar studies have gone: Previous studies have shown that LAAO is effective in stroke prevention, but this specific comparison of low-dose NOACs versus GDMT is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Non-valvular atrial fibrillation (NVAF) patients with successful left atrial appendage occlusion (LAAO) 2. Eligible for guideline-directed anti-thrombotic therapy 3. Able to understand and provide informed consent and comply with all study medications Exclusion Criteria: 1. Under the age of 18 2. Unable to give informed consent or currently participating in another trial and not yet at its primary endpoint 3. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential according to local practice) 4. Concurrent medical condition with a life expectancy of less than two years 5. Haemodynamical unstable 6. Known contraindication to medications such as heparin, antiplatelet or anticoagulation drugs, or contrast 7. Peridevice leak \> 5mm as assessed immediately after LAAO or any other procedure-related complications 8. Comorbidities other than atrial fibrillation that required long term use of anticoagulation (such as implanted mechanical valve) 9. Percutaneous coronary intervention (PCI) within 1 year. 10. The patient had or is planning to have any cardiac or non-cardiac interventional or surgical procedure within 30 days prior to or 60 days after the WATCHMAN device implant (e.g., PCI, cardioversion, cardiac surgery) 11. Ongoing overt bleeding 12. Previous stroke/TIA within 30 days of enrolment 13. Symptomatic carotid artery disease 14. Severe renal insufficiency (CrCl≤30ml/min/1.73m2)
Where it's running
-
Ling Tao
Xi'an, Shannxi, China Recruiting
Study contacts
- Study coordinator: Chao Gao, M.D., Ph.D.
- Email: woshigaochao@gmail.com
- Phone: +86-18629551066
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation
This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.
-
Identifying AF patients who may need more than standard ablation using Volta AF-Xplorer II
This trial tests whether AI-identified dispersion areas during AF ablation can predict recurrence after a standard pulmonary vein isolation in patients with persistent AF.
-
4D intracardiac echocardiography to guide left atrial appendage occlusion procedures
A new 4D ICE catheter is being tested alongside standard imaging to see if it can safely guide left atrial appendage occlusion procedures for adults with atrial fibrillation.
-
Thoracoscopic vs Catheter Ablation as the First Rhythm Control in Atrial Fibrillation with a Large Left Atrium
This trial tests whether thoracoscopic surgical ablation is better at keeping atrial fibrillation under control than catheter ablation in people with persistent AF and a large left atrium who have not had an ablation before.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.